Edition:
United States

Oragenics Inc (OGEN.A)

OGEN.A on American Stock Exchange

0.59USD
2 Dec 2016
Change (% chg)

$0.08 (+15.95%)
Prev Close
$0.51
Open
$0.53
Day's High
$0.62
Day's Low
$0.53
Volume
2,333
Avg. Vol
16,941
52-wk High
$2.06
52-wk Low
$0.34

Latest Key Developments (Source: Significant Developments)

Oragenics receives supportive FDA feedback for initiating a phase 2 study protocol for Oral Mucositis Treatment
Tuesday, 30 Aug 2016 08:15am EDT 

Oragenics Inc : Oragenics receives supportive FDA feedback for initiating a phase 2 study protocol for Oral Mucositis Treatment . Expects to file Investigational New Drug (ind) update in late 2016 . Oragenics Inc says to initiate study with ag013 in united states and europe during early 2017 .Applications for biologic license application exclusivity and fast track designation with FDA will be filed in coming months.  Full Article

Oragenics Inc files for stock shelf of upto $30 mln
Thursday, 25 Aug 2016 05:24pm EDT 

Oragenics Inc :Files for stock shelf of upto $30 million - SEC filing.  Full Article

Oragenics Inc says Alan Joslyn to be new president and CEO
Monday, 6 Jun 2016 04:51pm EDT 

Oragenics Inc : Oragenics announces new president, chief executive officer and member of the board of directors .Oragenics Inc says Alan Joslyn will be company's new president and chief executive officer.  Full Article

Intrexon Corp and Oragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study
Tuesday, 28 Jul 2015 04:05pm EDT 

Intrexon Corp and Oragenics:Says positive data on multiple compounds from Oragenics' Mutacin 1140 lantibiotic platform in a critical animal model study, as well as the selection of a lead clinical candidate.The compounds were subjected to a standardized proof of concept animal model evaluating efficacy for reducing clinically relevant C. difficile infection(s) and increased survival relative to vancomycin positive control.  Full Article

Intrexon Corp and Oragenics expand collaboration to pursue development of biotherapeutics for Oral Cavity
Wednesday, 10 Jun 2015 08:15am EDT 

Intrexon Corp and Oragenics:Says new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, including clinical advancement of the ActoBiotic AG013 for the treatment of OM.OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually.At present there is no drug approved to prevent the condition broadly and therapies are primarily palliative, alleviating symptoms without addressing the underlying pathology, resulting in a significant unmet medical need.  Full Article

Oragenics Inc to explore strategic alternatives for OTC Probiotic Products Business
Monday, 22 Dec 2014 04:54pm EST 

Oragenics Inc:Authorizes the exploration of strategic alternatives with respect to the Company's over-the counter (OTC) probiotic business.These alternatives could include joint ventures, strategic partnerships or alliances, a sale of the OTC probiotic products business or other possible transactions.There can be no assurance that the board's evaluation process will result in any transaction, or that any transaction, if pursued, will be consummated.We do not currently intend to disclose further developments with respect to this process or provide any additional information unless or until our board of directors approves a specific transaction or otherwise concludes the evaluation process.  Full Article

BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis

* U.S. FDA grants fast track designation for the development of Oragenics' AG013 for oral mucositis